AR014762A1 - PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAE - Google Patents
PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAEInfo
- Publication number
- AR014762A1 AR014762A1 ARP990101271A ARP990101271A AR014762A1 AR 014762 A1 AR014762 A1 AR 014762A1 AR P990101271 A ARP990101271 A AR P990101271A AR P990101271 A ARP990101271 A AR P990101271A AR 014762 A1 AR014762 A1 AR 014762A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccines
- hib
- procedure
- interference
- combination vaccines
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 241000606768 Haemophilus influenzae Species 0.000 title abstract 2
- 229940047650 haemophilus influenzae Drugs 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 239000002671 adjuvant Substances 0.000 abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 2
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 229940032047 Tdap vaccine Drugs 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 229940031670 conjugate vaccine Drugs 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se trata de un procedimiento general mediante el cual se pueden prepararse vacunas de Hib/DTPa líquida o preparada extemporáneamente, con el fin de evitarla interferencia de Hib al mismo tiempo que se mantiene la absorcion máxima estable de cadaantígeno sobre el adyuvante con una base de aluminio sobre elcual resulta más inmunogena. Mediante este procedimiento, los antígenos de pertussis en vacunas de combinacion de la presente invencion se mantienen en suforma más potente de una manera estable. Específicamente dicho procedimiento permite reducir la interferencia de los componentes polisacáridos capsulares deuna vacuna conjugada de Haemophilus influenzae B (Hib) en vacunas de combinacion que comprende DTPa, caracterizado dicho procedimiento porque comprende: (i)seleccionar uno o más antígeno(s) para adsorberlos sobre un adyuvante de hidroxido de aluminio; (ii) presaturar el adyuvante de hidroxido de aluminiocon los antígenos seleccionados; (iii) seleccionar uno o más antígeno(s) para adsorberlos sobre fosfato de aluminio; (iv) adsorber Hib y dichos antígenosadicionales citados sobre fosfato de aluminio; (v) combinar todos los antígenos en dichas vacunas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806456.1A GB9806456D0 (en) | 1998-03-25 | 1998-03-25 | Vaccine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR014762A1 true AR014762A1 (es) | 2001-03-28 |
Family
ID=10829286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101271A AR014762A1 (es) | 1998-03-25 | 1999-03-23 | PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAE |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1066053B8 (es) |
JP (1) | JP2002507581A (es) |
KR (1) | KR20010034630A (es) |
CN (1) | CN1295481A (es) |
AR (1) | AR014762A1 (es) |
AT (1) | ATE335509T1 (es) |
AU (1) | AU735619B2 (es) |
BR (1) | BR9909037A (es) |
CA (1) | CA2325436A1 (es) |
CO (1) | CO4820442A1 (es) |
CZ (1) | CZ20003536A3 (es) |
DE (1) | DE69932709T2 (es) |
ES (1) | ES2270590T3 (es) |
GB (1) | GB9806456D0 (es) |
HU (1) | HUP0101323A1 (es) |
IL (1) | IL137999A0 (es) |
MY (1) | MY133780A (es) |
NO (1) | NO20004758L (es) |
NZ (1) | NZ506604A (es) |
PL (1) | PL343065A1 (es) |
TR (1) | TR200002737T2 (es) |
WO (1) | WO1999048525A1 (es) |
ZA (1) | ZA200004956B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020054884A1 (en) | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
EP1004314A1 (fr) * | 1998-11-26 | 2000-05-31 | Pasteur Merieux MSD | Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
PT1296715E (pt) * | 2000-06-29 | 2012-01-19 | Smithkline Beecham Biolog | Composição vacinal multivalente |
KR100385711B1 (ko) * | 2000-07-05 | 2003-05-27 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드와 백일해균 및b형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법 |
KR100401423B1 (ko) * | 2001-01-10 | 2003-10-17 | 주식회사 엘지생명과학 | 혼합 백신의 제조 방법 |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
RU2323002C2 (ru) * | 2001-07-26 | 2008-04-27 | Чирон Срл. | Вакцины, содержащие алюминиевые адъюванты и гистидин |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
FR2828406B1 (fr) * | 2001-08-08 | 2005-06-24 | Aventis Pasteur | Composition vaccinale bivalente havi |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0223355D0 (en) * | 2002-10-08 | 2002-11-13 | Chiron Spa | Vaccine |
ES2649048T3 (es) | 2002-11-01 | 2018-01-09 | Glaxosmithkline Biologicals S.A. | Procedimiento de secado |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
CA2530434A1 (en) * | 2003-06-23 | 2005-01-06 | Aventis Pasteur, Inc. | Immunization method against neisseria meningitidis serogroups a and c |
US7867715B2 (en) | 2003-08-05 | 2011-01-11 | Alk-Abello A/S | Method of evaluating the immunological activity of a vaccine |
GB2429207A (en) | 2004-02-02 | 2007-02-21 | Ambrx Inc | Modified human interferon polypeptides and their uses |
KR101408113B1 (ko) | 2005-06-27 | 2014-06-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
GB0617602D0 (en) * | 2006-09-07 | 2006-10-18 | Glaxosmithkline Biolog Sa | Vaccine |
AU2007293673B2 (en) | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
PE20100366A1 (es) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
ES2850973T3 (es) | 2010-08-23 | 2021-09-01 | Wyeth Llc | Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis |
WO2012032489A1 (en) | 2010-09-10 | 2012-03-15 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
CN102198270B (zh) * | 2011-05-16 | 2012-06-27 | 大连汉信生物制药有限公司 | 一种含铝佐剂乙肝疫苗的制备方法 |
CN104159603A (zh) * | 2012-03-08 | 2014-11-19 | 诺华股份有限公司 | 带有tlr4激动剂的联合疫苗 |
NZ628449A (en) | 2012-03-09 | 2016-04-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
DK2863943T3 (en) | 2013-03-08 | 2016-11-07 | Janssen Vaccines & Prevention Bv | acellular pertussis vaccines |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
CN110234658B (zh) | 2017-01-31 | 2024-03-12 | 辉瑞大药厂 | 脑膜炎奈瑟菌组合物及其使用方法 |
CN111032078A (zh) | 2017-07-18 | 2020-04-17 | 血清研究所印度私人有限公司 | 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法 |
EP3749354A4 (en) * | 2018-02-05 | 2021-11-03 | Diamyd Medical AB | NEW COMPOSITION AND ITS USE |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0835663B1 (en) * | 1992-05-23 | 2009-09-30 | GlaxoSmithKline Biologicals S.A. | Combined vaccines comprising Hepatitis B surface antigen and other antigens |
CA2222455C (en) * | 1995-03-22 | 2013-05-28 | Smithkline Beecham Biologicals S.A. | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
GB9611501D0 (en) * | 1996-06-03 | 1996-08-07 | Smithkline Beecham Biolog | Vaccine compositions |
-
1998
- 1998-03-25 GB GBGB9806456.1A patent/GB9806456D0/en not_active Ceased
-
1999
- 1999-03-22 ES ES99915692T patent/ES2270590T3/es not_active Expired - Lifetime
- 1999-03-22 CZ CZ20003536A patent/CZ20003536A3/cs unknown
- 1999-03-22 IL IL13799999A patent/IL137999A0/xx unknown
- 1999-03-22 AU AU34172/99A patent/AU735619B2/en not_active Ceased
- 1999-03-22 CA CA002325436A patent/CA2325436A1/en not_active Abandoned
- 1999-03-22 AT AT99915692T patent/ATE335509T1/de not_active IP Right Cessation
- 1999-03-22 HU HU0101323A patent/HUP0101323A1/hu unknown
- 1999-03-22 PL PL99343065A patent/PL343065A1/xx unknown
- 1999-03-22 TR TR2000/02737T patent/TR200002737T2/xx unknown
- 1999-03-22 JP JP2000537572A patent/JP2002507581A/ja active Pending
- 1999-03-22 DE DE69932709T patent/DE69932709T2/de not_active Expired - Lifetime
- 1999-03-22 EP EP99915692A patent/EP1066053B8/en not_active Expired - Lifetime
- 1999-03-22 NZ NZ506604A patent/NZ506604A/xx unknown
- 1999-03-22 BR BR9909037-6A patent/BR9909037A/pt not_active IP Right Cessation
- 1999-03-22 WO PCT/EP1999/001959 patent/WO1999048525A1/en active IP Right Grant
- 1999-03-22 CN CN99804445A patent/CN1295481A/zh active Pending
- 1999-03-22 KR KR1020007010518A patent/KR20010034630A/ko not_active Application Discontinuation
- 1999-03-23 AR ARP990101271A patent/AR014762A1/es not_active Application Discontinuation
- 1999-03-23 MY MYPI99001093A patent/MY133780A/en unknown
- 1999-03-25 CO CO99018131A patent/CO4820442A1/es unknown
-
2000
- 2000-09-18 ZA ZA200004956A patent/ZA200004956B/xx unknown
- 2000-09-22 NO NO20004758A patent/NO20004758L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1999048525A1 (en) | 1999-09-30 |
NO20004758D0 (no) | 2000-09-22 |
BR9909037A (pt) | 2000-12-05 |
CZ20003536A3 (cs) | 2001-08-15 |
NZ506604A (en) | 2003-02-28 |
AU3417299A (en) | 1999-10-18 |
TR200002737T2 (tr) | 2000-12-21 |
CN1295481A (zh) | 2001-05-16 |
IL137999A0 (en) | 2001-10-31 |
HUP0101323A1 (hu) | 2001-08-28 |
JP2002507581A (ja) | 2002-03-12 |
ATE335509T1 (de) | 2006-09-15 |
CA2325436A1 (en) | 1999-09-30 |
KR20010034630A (ko) | 2001-04-25 |
EP1066053A1 (en) | 2001-01-10 |
MY133780A (en) | 2007-11-30 |
WO1999048525A8 (en) | 1999-11-11 |
PL343065A1 (en) | 2001-07-30 |
DE69932709D1 (de) | 2006-09-21 |
EP1066053B1 (en) | 2006-08-09 |
EP1066053B8 (en) | 2006-12-13 |
AU735619B2 (en) | 2001-07-12 |
DE69932709T2 (de) | 2007-08-16 |
ES2270590T3 (es) | 2007-04-01 |
CO4820442A1 (es) | 1999-07-28 |
GB9806456D0 (en) | 1998-05-27 |
NO20004758L (no) | 2000-11-08 |
ZA200004956B (en) | 2002-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR014762A1 (es) | PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAE | |
EA200501070A1 (ru) | Поливалентная вакцинная композиция | |
AR003006A1 (es) | Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento | |
NZ596870A (en) | Vaccine compositions comprising a saponin adjuvant | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
RU2012116119A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
LU91734I2 (fr) | Menveo - oligosaccharide méningococcique du group Y conjugué à la protéine CRM197 de Corynebacteriumdiphteriae. | |
ES2179105T3 (es) | Adyuvantes proteinicos. | |
BRPI0508813A (pt) | vacinas de combinação com baixa dose de conjugado de hib | |
DK1635863T3 (da) | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål | |
AR026940A1 (es) | Composicion farmaceuticas para modulacion inmunologica y preparacion de vacunas | |
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
AR066376A1 (es) | Vacuna | |
BR0212556A (pt) | interleucina-12 como um adjuvante de vacina veterinária | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
CY1112149T1 (el) | Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο | |
WO2005021726A3 (en) | Immunogenic hiv compositions and related methods | |
ATE329615T1 (de) | Borrelia burgdorferi bacterin | |
WO2002032455A3 (en) | Vaccine | |
TW202423477A (zh) | 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物 | |
DK1183044T3 (da) | Adjuvanskombinationer til immunisering og vacciner | |
ECSP961797A (es) | Vacunas que comprende un antigeno conjugado polisacarido | |
CO4480037A1 (es) | Vacunas que comprenden un antigeno polisacarido conjugado unido a una proteina portadora y adsorbido sobre fosfato de aluminio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |